{"disease":{"id":"x-linked-retinitis-pigmentosa-xlrp","name":"x linked retinitis pigmentosa xlrp"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06982417","title":"InsightRP2 Registry","phase":"","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"University of Göttingen","has_results":false},{"nct_id":"NCT06492850","title":"Gene Therapy for RPGR Gene Mutation-associated X-linked Retinitis Pigmentosa","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":32,"lead_sponsor_name":"Frontera Therapeutics","has_results":false},{"nct_id":"NCT07174726","title":"A Phase 2 Open-label Study to Evaluate the Safety of Laruparetigene Zovaparvovec Administered Bilaterally in Male Participants With X-Linked Retinitis Pigmentosa","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":10,"lead_sponsor_name":"Beacon Therapeutics","has_results":false}],"total":3},"guidelines":[],"source":"Drug Landscape verified database"}